GH001 Shows Strong Efficacy in Anhedonia, Anxiety, and Quality of Life, Independent of Prior Treatment Failures

summarizeSummary

GH Research presented new Phase 2b data for GH001, showing significant improvements in anhedonia, anxiety, and quality of life in treatment-resistant depression, with efficacy maintained regardless of prior treatment failures.

check_boxKey Events

• GH001 Improves Anhedonia

  GH001 demonstrated rapid and sustained reduction in anhedonia symptoms, with a -9.9 point reduction in MADRS anhedonia factor score versus placebo at Day 8 (P<0.0001), and sustained improvements at 6 months in the open-label extension.

• Efficacy Independent of Prior Treatment Failures

  The efficacy of GH001 in treatment-resistant depression was consistent across patients with varying numbers of prior antidepressant treatment failures, a significant finding that contrasts with the progressive efficacy decline seen in other studies like STAR*D.

• Broad Impact on Symptoms and Quality of Life

  Statistically significant improvements were observed across secondary efficacy endpoints, including overall illness severity (CGI-S), anxiety (HAM-A), and patient-reported quality of life (Q-LES-Q-SF) at Day 8, with these benefits sustained through 6 months.

auto_awesomeAnalysis

This 6-K details new post-hoc analyses from the Phase 2b trial of GH001 in treatment-resistant depression (TRD). The findings significantly strengthen the drug's profile by demonstrating rapid and sustained improvements in anhedonia, anxiety, and overall quality of life. Crucially, the data indicates that GH001's efficacy is independent of the number of prior antidepressant treatment failures, a key differentiator in TRD where other treatments show declining efficacy with increased resistance. These results provide a more comprehensive understanding of GH001's broad therapeutic potential as the company prepares for Phase 3.